A story card from The Whole Day: Personalized mRNA Vaccine Cuts Melanoma Recurrence by 42%

Personalized mRNA Vaccine Cuts Melanoma Recurrence by 42%

In the global Phase 3 INTerpath-001 trial involving 1,137 patients, adding the personalized mRNA vaccine intismeran autogene to standard pembrolizumab immunotherapy after surgery reduced the risk of recurrence or death in high-risk melanoma by 42% compared to pembrolizumab alone. Each patient’s vaccine is custom-manufactured by sequencing their tumor DNA to target up to 34 patient-specific neoantigens. At two years, 82.2% of combination-treated patients remained recurrence-free versus 70.0% on monotherapy. The landmark study marks the first late-stage Phase 3 confirmation that individualized mRNA cancer vaccines can significantly prevent post-surgical disease relapse.

ASCO Post · Oct 26, 2026

Read on The Whole Day →